CD274 and hepatocellular carcinoma: In the Checkmate-459 trial, which compared nivolumab vs. sorafenib for advanced HCC, patients with PD-L1 ≥1% achieved a higher response rate with nivolumab compared to those with PD-L1 expression <1% (28% vs. 12%).